Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression

Obesity

Volumn 21, Issue 12, 2013, Pages

  Brown, Meredith V ^a   Compton, Sarah A ^b   Milburn, Michael V ^a   Lawton, Kay A ^a   Cheatham, Bentley ^b  

^a METABOLON INC   (United States)

^b Zen Bio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CARNITINE; DIACYLGLYCEROL; MONOACYLGLYCEROL; SPHINGOSINE;

ARTICLE; BILE ACID METABOLISM; CONTROLLED STUDY; DISEASE COURSE; IN VITRO STUDY; INSULIN RESISTANCE; LIPOTOXICITY; METABOLOMICS; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

BILE ACIDS AND SALTS; DIGLYCERIDES; DISEASE PROGRESSION; FATTY LIVER; HEK293 CELLS; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; METABOLOME; MITOCHONDRIA; MONOGLYCERIDES; OLEIC ACID; OXIDATIVE STRESS; PALMITIC ACID; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES;

EID: 84889675838     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20440     Document Type: Article

References (40)

1. Erickson SK,. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50: S412-S416.
2. Dunn W, Schwimmer JB,. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008; 10: 67-72.
3. Angulo P,. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
4. Wei Y, Rector RS, Thyfault JP, Ibdah JA,. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-199.
5. Dowman JK, Tomlinson JW, Newsome PN,. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.
6. Smith BW, Adams LA,. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011; 7: 456-465.
7. Savage DB, Petersen KF, Shulman GI,. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007; 87: 507-520.
8. Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
9. Rolo AP, Teodoro JS, Palmeira CM,. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69.
10. Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404-413.
11. Pilvi TK, Seppanen-Laakso T, Simolin H, et al. Metabolomic changes in fatty liver can be modified by dietary protein and calcium during energy restriction. World J Gastroenterol 2008; 14: 4462-4472.
12. Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A,. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. J Proteome Res 2011; 10: 4825-4834.
13. de Wit NJ, Afman LA, Mensink M, Muller M,. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 2012; 57: 1370-1373.
14. Kim HJ, Kim JH, Noh S, et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res 2011; 10: 722-731.
15. Vulimiri SV, Misra M, Hamm JT, Mitchell M, Berger A,. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem Res Toxicol 2009; 22: 492-503.
16. Watson M, Roulston A, Belec L, et al. The small molecule GMX1778 is a potent inhibitor of NAD + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009; 29: 5872-5888.
17. Wetmore DR, Joseloff E, Pilewski J, et al. Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. J Biol Chem 2010; 285: 30516-30522.
18. Malhi H, Bronk SF, Werneburg NW, Gores GJ,. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006; 281: 12093-12101.
19. Nakamura S, Takamura T, Matsuzawa-Nagata N, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 2009; 284: 14809-14818.
20. Kanebratt KP, Andersson TB,. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 2008; 36: 1444-1452.
21. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E,. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-6667.
22. Brown MV, McDunn JE, Gunst PR, et al. Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med 2012; 4: 33.
23. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103: 1006-1011.
24. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P,. Bile acids as regulatory molecules. J Lipid Res 2009; 50: 1509-1520.
25. Chavez JA, Summers SA,. A ceramide-centric view of insulin resistance. Cell Metab 2012; 15: 585-594.
26. Sunny NE, Parks EJ, Browning JD, Burgess SC,. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810.
27. Sunny Nishanth E, Parks Elizabeth J, Browning Jeffrey D, Burgess Shawn C,. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810.
28. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-326.
29. Gorden DL, Ivanova PT, Myers DS, et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One 2011; 6: e22775.
30. Yetukuri L, Katajamaa M, Medina-Gomez G, Seppanen-Laakso T, Vidal-Puig A, Oresic M,. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. Biomed Chromatogr Syst Biol 2007; 1: 12.
31. Neuschwander-Tetri BA,. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788.
32. Jornayvaz FR, Shulman GI,. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab 2012; 15: 574-584.
33. Montell E, Turini M, Marotta M, et al. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab. 2001; 280: E229-E237.
34. Wei Y, Wang D, Pagliassotti MJ,. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Mol Cell Biochem 2007; 303: 105-113.
35. Adams JM, 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53: 25-31.
36. Xia Y, Li Q, Zhong W, Dong J, Wang Z, Wang C,. L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 2011; 3: 31.
37. Newgard CB,. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15: 606-614.
38. McCormack SE, Shaham O, McCarthy MA, et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 2012;8:52-61.
39. Wei J, Qiu de K, Ma X,. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J Dig Dis 2009; 10: 85-90.
40. Li LO, Hu YF, Wang L, Mitchell M, Berger A, Coleman RA,. Early hepatic insulin resistance in mice: a metabolomics analysis. Mol Endocrinol 2010; 24: 657-666.